Introduction: This phase I study evaluated nivolumab combined with erlotinib in patients with advanced EGFRmutant NSCLC.
plus erlotinib. Treatment-related grade 3 toxicities occurred in five patients (liver enzyme elevations, n ¼ 2; diarrhea, n ¼ 2; weight loss, n ¼ 1), with no grade !4 toxicities. In the TKI-treated population, the objective response rate was 15% (3 of 20, including one complete response), and the 24-week progression-free survival rate was 48%. Responses lasted 13.8, 17.6, and 38.2 months per investigator records. A fourth patient had a nonconventional immune-related response lasting 12.5 months. Among these four patients, two were never-smokers and one each had 35-and <1-pack-year histories. Post-EGFR TKI pre-trial tumor biopsy specimens from these patients detected EGFR T790M mutations in two patients and MNNG HOS Transforming gene (MET) amplification in a third; two patients each had primary EGFR exon 19 deletions or L858R mutations. The TKI-naive patient, who had compound EGFR mutations (L858R and S768I) and ultimately achieved a complete response, had an ongoing response lasting more than 5 years based on investigator records.
Introduction
Activating EGFR mutations are found in approximately 15% of adenocarcinomas of the lung in White populations. In Asian populations, EGFR mutations can be identified in 50% or more of adenocarcinomas of the lung. 1 Currently, erlotinib, gefitinib, and afatinib-smallmolecule EGFR tyrosine kinase inhibitors (TKIs)-are approved for first-line use in patients with EGFR-mutant lung cancer in numerous countries, with objective response rates (ORRs) of 56% to 83%, median progression-free survival (PFS) of 9.5 to 13.6 months, and median overall survival (OS) of 19.3 to 30.5 months. [2] [3] [4] [5] [6] [7] [8] On the emergence of resistance to EGFR TKIs, a second EGFR mutation in exon 20, T790M, can be found in resistant tumor biopsy specimens from approximately half of patients, where it is believed to be the primary mediator of such resistance (other potential mediators of acquired resistance to EGFR TKIs include histologic transformation to small cell carcinoma and MNNG HOS Transforming gene [MET] amplification). 9, 10 If EGFR T790M is detected at the time of resistance to first-line EGFR TKI treatment, either in tumor cells or as free circulating mutant DNA in blood, osimertinib, a third-generation EGFR mutation-specific TKI, is indicated. ORR with osimertinib in this setting was 71%, with a median PFS of 10.1 months. 11 Recently, osimertinib was granted priority review in the United States as frontline therapy for advanced EGFR-mutant NSCLC. This was based on a phase III trial that showed a PFS benefit in EGFR TKI-naive patients compared with either erlotinib or gefitinib (median PFS of 18.9 months versus 10.2 months; hazard ratio ¼ 0.46, 95% confidence interval [CI]: 0.37-0.57, p < 0.001). 12 Data evaluating standard chemotherapy after the development of resistance to first-line EGFR TKI treatment are limited. One phase III trial reported a median PFS and OS of 5.4 months and 17.2 months with platinum-doublet chemotherapy, respectively, regardless of T790M status; ORR was 34% with chemotherapy in this study. 13 Another trial found median PFS and ORR to be 4.4 months and 31% with chemotherapy, respectively, in patients with T790M-positive disease.
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Three programmed death-1 (PD-1) axis inhibitor antibodies have been approved in the United States, Canada, and Europe for use in patients with advanced NSCLC. Nivolumab, a fully human PD-1 immune checkpoint inhibitor antibody, is indicated following disease progression on first-line platinum-based chemotherapy, irrespective of tumor programmed death-ligand 1 (PD-L1) expression. Relatively few patients with EGFR mutations were included in the trials establishing the use of PD-1 axis inhibitors in advanced NSCLC. A meta-analysis evaluating this population suggested little benefit with PD-1 axis inhibitor therapy over standard second-line chemotherapy with docetaxel. 14 CheckMate 012 (NCT01454102) is a multiarm phase I study evaluating nivolumab in combination with different agents including erlotinib, bevacizumab, ipilimumab, or platinum-doublet chemotherapy in advanced NSCLC. Herein we present the safety and efficacy of nivolumab combined with erlotinib in a cohort of patients with chemotherapy-naive EGFR-mutated advanced NSCLC.
Material and Methods

Study Design and Treatment
CheckMate 012 was approved by local institutional review boards, and all patients provided written informed consent before enrollment. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, as defined by the International Conference on Harmonisation. The primary objective was the safety and tolerability of nivolumab plus erlotinib, measured by the frequency of adverse events (AEs) and serious AEs, including laboratory abnormalities occurring up to 100 days after the last dose of study drug. The secondary objective was antitumor activity of nivolumab combined with erlotinib, measured by ORR and 24-week PFS rate per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). 15 Median PFS and OS were assessed as prespecified exploratory endpoints. Patients received nivolumab 3 mg/kg as a 60-minute intravenous infusion every 2 weeks and oral erlotinib 150 mg daily until progressive disease (PD), discontinuation due to toxicity, or withdrawal of consent. Patients could continue study drug(s) beyond PD if they were considered by the investigator to be deriving clinical benefit and tolerating study treatment.
Patients
Patients had chemotherapy-naive, measurable, and histologically or cytologically confirmed stage IIIB/IV nonsquamous NSCLC harboring an EGFR mutation (based on site-determined EGFR mutation tests). 16 Patients aged 18 years or older with Eastern Cooperative Oncology Group performance status 0 or 1, adequate organ function, and life expectancy of at least 3 months were eligible. Prior EGFR-TKI therapy was allowed. Patients with asymptomatic, controlled brain metastases who completed radiotherapy at least 2 weeks before initiation of study treatment or who received surgery or radiosurgery at least 2 weeks before enrollment were permitted. Patients with a history of chronic autoimmune disease, interstitial lung disease, and those with evidence of active infection with hepatitis B or C or known history of HIV/AIDS were excluded. Unless used in the management of a treatment-related AE, immunosuppressive agents or immunosuppressive doses of systemic corticosteroids (e.g., prednisone >10 mg/d) were prohibited during the study, as were any concurrent immunotherapies or standard or investigational agents for the treatment of NSCLC.
Study Assessments
Severity of AEs was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0; the causal association with study drug was assessed by the investigators. Tumor response was assessed by the investigators at the beginning of weeks 11, 17, and 23, and then every 3 months until PD. For patients who discontinued for reasons other than PD, tumor assessments were performed per the protocol-defined schedule until PD. For patients who continued nivolumab beyond progression, a follow-up scan was performed within 6 weeks, and evaluations then continued on study as described above. Treatment was discontinued upon documented further progression, defined as an additional 10% increase in tumor burden in all target and any new measurable lesions from the time of initial PD. Two follow-up visits to assess safety occurred 30 and 100 days after the last dose or date of discontinuation.
Survival was assessed every 12 weeks after the second follow-up visit.
PD-L1 expression was measured postenrollment in pretreatment (archival or fresh) tumor samples using a validated, automated immunohistochemical assay (Dako, North America, Carpinteria, California) that used a rabbit antihuman PD-L1 antibody (clone 28-8; Epitomics, Burlingame, California). The expression level was measured as the percentage of tumor cells with membrane staining (any intensity) in a section containing at least 100 evaluable tumor cells.
Statistical Analyses
Reported analyses were based on the final database lock for this cohort (September 19, 2016) . Additional data were collected after the database lock through December 1, 2017, as allowed by each separate institution. Baseline characteristics and AE frequency were summarized using descriptive statistics. For determination of the total number of patients with an AE, patients were counted only once at the preferred term, system organ class, and patient levels, based on the worst grade on treatment. All tumor assessments up to initial PD or initiation of subsequent anticancer therapy, whichever occurred first, were considered to assess best overall response per RECIST v1.1. ORR was defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR), with two-sided 95% exact CIs calculated using the ClopperPearson method. 17 PFS was defined from the date of first dose of study medication to the date of first disease progression or death, if death occurred within 100 days of the final dose of study medication. Among patients without previous RECIST-defined progression, patients who died beyond 100 days and those who remained alive were censored at the last tumor assessment date (before subsequent therapy). PFS rate at 24 weeks was defined as the proportion of all treated patients who remained alive and progression-free at 24 weeks. Timeto-event endpoints (PFS and OS) were estimated using the Kaplan-Meier method, with two-sided 95% CIs for medians and rates calculated using standard methods. 18 
Results
Patient Characteristics and Disposition
The minimum follow-up for this cohort of patients was 49 months (defined as the time from the last enrolled patient's first treatment to the database lock). The median follow-up was 19.3 months (range, 5.9-49.7 months). Median age was 63 years (range, 41-80 years), 62% of patients were female, 95% had stage IV disease at study entry, and 62% were never-smokers ( a This patient exhibited a nonconventional "immune-related" response, with a 61% maximum reduction in target lesion after initial progression in non-target lesions; best change from baseline was -14.3% before progression in non-target lesions; b TKI-naive patient. (C) Percent change in target lesion tumor burden over time from baseline by PD-L1 expression. Patients with a baseline and at least one post-baseline target lesion assessment are presented in B and C based on a September 2016 database lock. Bev, bevacizumab; carbo, carboplatin; cis, cisplatin; CMV, cisplatin þ mitomycin þ vinblastine; CR, complete response; daco, dacomitinib; Del19, exon 19 deletion mutation; EGFR, epidermal growth factor receptor; erl, erlotinib; inh., inhibitor; max, maximum; MET, MNNG HOS Transforming gene; mut., mutation; na, not available; neg, negative; nivo, nivolumab monotherapy continuation; NSCLC, non-small cell lung cancer; OS, overall survival; osim, osimertinib; pac, paclitaxel; pem, pemetrexed; PD, progressive disease; PD-L1, programmed death-ligand 1; pos, positive; PR, partial response; PY, pack-year; ruxo, ruxolitinib; SD, stable disease; SNX, SNX-5422; TKI, tyrosine kinase inhibitor.
patients treated, 1 patient was TKI-naive and 20 had received prior erlotinib. All previously treated patients had discontinued prior erlotinib due to PD. Patients had received prior erlotinib for a median of 16.6 months (range, 0.5-44.2 months). Median time from last EGFRtargeted therapy to initiation of nivolumab plus erlotinib was 0.3 weeks (range, 0.1-52.6 weeks). Primary EGFR mutations included exon 19 deletions (57%) and exon 21 L858R (43%) (Fig. 1A) . One patient, who was TKI-naive, had compound primary EGFR mutations including L858R and S768I. Per investigator records, 14 patients underwent pretrial EGFR T790M analysis; T790M was detected in 6 patients. Additionally, one of seven patients was found to have tumor MET amplification.
Median duration of nivolumab therapy was 5.1 months (range, 0.5-49.7 months), with three patients (14%) still receiving nivolumab plus erlotinib at database lock. Median duration of erlotinib therapy was 5.7 months (range, 0.9-50.1 months). The relative dose intensity was at least 70% of the planned dose of nivolumab and erlotinib in 21 (100%) and 16 (76%) patients, respectively, and at least 90% of the planned dose in 16 (76%) and six (29%) patients. Among the 18 patients who discontinued study treatment, reasons for discontinuation were PD in 14 (67%) patients, study drug toxicity in two (10%) patients, and withdrawal of consent and maximum clinical benefit (one patient each).
Safety
All patients reported at least one treatment-related AE (TRAE) ( Table 2 ). Most TRAEs were low-grade (grade 1-2), and no grade 4 or 5 TRAEs were reported. Rash (n ¼ 10, 48%), fatigue (n ¼ 6, 29%), paronychia (n ¼ 6, 29%), and skin fissures (n ¼ 5, 24%) were the most common TRAEs. Eighteen (86%) patients had treatment-related select AEs (those of potential immune etiology) (Supplementary Table 1 ).
Five (24%) patients experienced grade 3 TRAEs, comprising increased aspartate aminotransferase (AST; n ¼ 1, 5%), increased alanine aminotransferase (ALT) and AST (n ¼ 1, 5%), diarrhea (n ¼ 2, 10%), and weight decrease (n ¼ 1, 5%). Dose delays occurred in 11 (52%) patients: these were due to nonhematologic toxicity (six patients, 29%), hematologic toxicity (one patient, 5%; this was subsequently found to be a data entry error after database lock), or other reasons (six patients, 29%). Treatment was discontinued in two (10%) patients due to TRAEs: one patient discontinued due to grade 3 diarrhea, and one patient discontinued due to grade 3 increased AST and grade 2 increased ALT. All grade 3 TRAEs and TRAEs leading to discontinuation resolved. Four patients discontinued erlotinib and continued on nivolumab monotherapy. Oral steroids were given per protocol-defined guidelines to two patients, and topical steroids were administered for TRAEs in nine patients. At database lock, 13 patients had died: 11 due to disease progression and two due to unknown causes.
Efficacy in TKI-Treated Patients
ORR was 15% (3 of 20, including 1 CR) in TKI-treated patients (Table 3 ). All objective responses occurred within 4 months of initiating trial therapy. One additional patient was observed to exhibit a nonconventional immune-related response with initial progression in nontarget lesions that subsequently regressed ( Supplementary Fig. 1 ), ultimately achieving a 61% maximum reduction in target lesions. Responses were observed regardless of specific mutation, including T790M (Fig. 1A, Table 4 ). Two of the three patients with a RECIST-defined response had a smoking history (less than 1 and 35 pack-years); the patient with the nonconventional response never smoked. Five patients achieved stable disease lasting more than 6 months per investigator judgement. Changes in target lesion tumor burden in the entire cohort of patients are shown in Figure 1B and C.
Kaplan-MeierÀestimated PFS rates at 24 weeks, 1 year, and 2 years were 48%, 30%, and 12%, respectively (Table 3 ; Fig. 2A ). Kaplan-Meier-estimated median PFS and OS were 5.1 months (95% CI: 2.3-12.1) and 18.7 months (95% CI: 7.3-not available). Kaplan-Meierestimated 1-, 2-, and 3-year OS rates were 70%, 40%, and 35% (Table 3 ; Fig. 2B ), respectively. In patients with a history of smoking (n ¼ 7) and never-smokers (n ¼ 13), respectively, Kaplan-Meier-estimated median PFS was 11.7 months and 2.8 months, and median OS was not reached and 16.5 months (Supplementary  Table 2) ; these comparisons were not tested statistically.
Among patients with evaluable PD-L1 expression (n ¼ 15), five (33%) had PD-L1 expression of at least 1%, three of whom were former smokers (Fig. 1A) . ORR was 20% (1 of 5) in patients with at least 1% tumor PD-L1 expression, 0% (0 of 10) in patients with less than 1% tumor PD-L1 expression, and 40% (2 of 5) among patients with unknown PD-L1 status (Supplementary Table 3 ). Note: Based on investigator records through December 1, 2017. Symbol þ indicates ongoing treatment or ongoing response. a Nivolumab and erlotinib were continued beyond PD, with local therapy to oligoprogressive sites. Patient with PD by RECIST version 1.1; however, this patient exhibited a nonconventional immune-related response, with a 61% reduction in target lesions (maximum decrease) after initial progression in non-target lesions. CR, complete response; Del19, exon 19 deletion mutation; DOR, duration of response; NA, not applicable; neg, negative; PD, progressive disease; pos, positive; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors. 
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Results in a TKI-Naive Patient
One patient with no prior TKI therapy was treated; she was a 67-year-old White female former smoker (82 pack-years) with stage IV adenocarcinoma harboring EGFR mutations L858R and S768I (Fig. 1A) . Pretreatment PD-L1 expression was 65%. PR was observed at 2.2 months following treatment initiation, which became a CR by 27.0 months after the first dose.
Long-Term Patient Follow-Up
Individual baseline mutational and PD-L1 status, along with clinical outcomes including subsequent therapy and additional follow-up after database lock (based on investigator records through December 1, 2017), are shown for all patients in Figure 1A . At database lock, 14 (67%) patients had received subsequent systemic therapy, among whom 8 (38%) received subsequent erlotinib (Supplementary Table 4) ; an additional 2 patients received subsequent therapy after database lock. Per investigator records, 8 patients were alive as of December 1, 2017 , all with OS of more than 5 years from trial entry. Among the TKI-treated patients, responses lasted 13.8 months and 17.6 months in the patients with PRs, 38.2 months in the patient with CR, and 12.5 months in the patient with immune-related response (Table 4) . Among these patients, three experienced progression at solitary sites that were treated locally. Two continued trial therapy beyond progression, with initiation of salvage systemic therapy 13 and 32 months after local therapy. The third patient underwent radiosurgery to a solitary central nervous system lesion 28 months after discontinuing therapy due to toxicity and had not received subsequent local or systemic therapy as of last follow-up, 20 months after radiosurgery (Fig. 1A) . The TKI-naive patient who ultimately achieved a CR continued nivolumab plus erlotinib with ongoing response lasting more than 5 years.
Discussion
The role of PD-1 axis inhibitors in patients with EGFR-mutant NSCLC is unclear. Preclinical studies have shown constitutive tumor PD-L1 expression driven by mutant EGFR signaling and slowed tumor growth with prolonged survival in EGFRmutant mouse models treated with an anti-PD-1 antibody. [19] [20] [21] [22] Despite these findings, subset analyses of recent clinical trials have reported low response rates to PD-1 axis inhibitors in patients with EGFRmutant lung cancer, with no improvement in OS compared with standard second-line chemotherapy. 14 However, small numbers of such patients and limited details concerning each patient (e.g., type of EGFR mutation or prior therapies) have precluded definitive conclusions.
In the current trial, at least 4 of 20 patients with acquired resistance to EGFR TKI treatment clearly benefited from adding PD-1 axis inhibitor therapy to EGFR TKI therapy. It is uncertain if continuing EGFR TKI therapy in this setting contributed to this benefit, although results in our small cohort suggest this may be the case with better outcomes than those reported with PD-1 axis inhibitor monotherapy in EGFR-mutant populations in other trials. [23] [24] [25] Duration of response to prior erlotinib treatment varied widely among the 20 patients with EGFR TKI resistance, ranging from 0.5 months to 44.2 months. Among the four patients with clear benefit from trial therapy, the time between stopping prior EGFR TKI and starting combination treatment on trial was short (0.1-4.0 weeks), with more durable benefit than prior therapy, supporting an effect of PD-1 axis inhibition.
Efforts now must focus on identifying which patients with EGFR-mutant NSCLC are most likely to benefit from PD-1 axis inhibitor therapy. In unselected patients with advanced NSCLC, smoking history, high tumor PD-L1 expression, and high tumor mutation burden appear to predict benefit, although individual responses have also been observed in patients without these characteristics. Of the 4 patients with clear benefit in our cohort of 20 patients with resistance to EGFR TKI therapy, one had a significant smoking history; only one patient had tumor tissue evaluable for PD-L1 expression (showing PD-L1 expression of 10%). Of the remaining 16 patients, 4 had a significant smoking history, and 13 had evaluable tumor specimens for PD-L1 expression, including 4 patients with tumor PD-L1 expression (ranging from 1% to 20%). Tumor mutation burden was not available; however, post-EGFR TKI pretrial results from local standard molecular profiling including EGFR mutational status and MET amplification were available from the four patients with clear benefit. Responses were seen regardless of primary EGFR mutation, presence of EGFR T790M, or MET amplification.
One patient in our study who had EGFR TKI-naive disease and ultimately achieved a CR on nivolumab plus erlotinib had an ongoing response lasting more than 5 years. This patient had a significant history of smoking and a high baseline level of tumor PD-L1 expression. CR to EGFR TKIs is rare, and a prolonged CR speaks to the potential of combination therapy with a known highly active therapy and a PD-1 axis inhibitor. Of course, our patient's response could be solely attributed to erlotinib, underscoring the need for serial tumor biopsy specimens to understand the effect of EGFR TKIs on the tumor microenvironment. Ongoing trials requiring such biopsies may help to answer this question.
To date, only two phase III trials have been launched evaluating PD-1 axis inhibitors in patients with EGFR-mutant lung cancer. The first, CAURAL (NCT02454933), randomized patients to the third-generation EGFR TKI osimertinib with or without durvalumab, an anti-PD-L1 antibody, and was closed prematurely due to increased incidence of pneumonitis, as was an earlier trial of the combination. 26 Further studies are needed to determine if there is an increased risk of developing pneumonitis when combining PD-1 axis inhibitors with osimertinib or other third-generation EGFR TKIs compared with firstor second-generation EGFR TKIs and to identify the mechanisms explaining this possible increased susceptibility. The second phase III trial investigating a PD-1 axis inhibitor in EGFR-mutant lung cancer, CheckMate 722 (NCT02864251), is ongoing and compares standard platinum-based doublet chemotherapy to either the same chemotherapy with concurrent nivolumab, or to combination therapy with nivolumab and ipilimumab, in patients with advanced TKI-pretreated EGFR-mutant NSCLC without EGFR T790M. 27 In support of the latter combination, 4 of 8 patients (50%) with EGFR-mutant lung cancer treated on trial with concurrent nivolumab and ipilimumab in a separate cohort of CheckMate 012 achieved a RECIST v1.1 response. 28 In summary, the addition of nivolumab to erlotinib was well tolerated and showed clinical activity in patients with erlotinib-resistant advanced EGFR-mutant NSCLC. Additional studies are warranted to further evaluate PD-1 axis inhibitors in patients with advanced EGFR-mutant NSCLC and to determine clinical and tumor characteristics that may predict benefit with PD-1 axis inhibition in this special NSCLC subpopulation.
